Indian stocks: Visit www.stage2stocks.com →

Amgen Inc.

Stage 2 · Advancing · week 16

As of Oct 22, 2026, Amgen is in Stage 2, the uptrend phase, now in week 16 (since Jul 6, 2026). It closed at $447.28, at its 52-week high and above its 200-day average, which is rising.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. More about the company

$447.28
+2.04% today
$242B · Large cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 9 in Drug Manufacturers - General · #1 of 272 in Health Care

Is AMGN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 28w
S2 22w
S2 25w
S2 16w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 3w → S2 28w → S3 8w → S2 22w → S3 8w → S4 10w → S1 6w → S2 4w → S3 1w → S4 9w → S1 2w → S2 7w → S3 6w → S1 1w → S2 25w → S3 9w → S2 16w current
Total tracked: 166 weeks across 17 stage runs.

AMGN among Drug Manufacturers - General4th of 21 by relative strength

All 21 →
Stocks in Drug Manufacturers - General ranked by relative strength, with stage and one-month change
#StockStageRS1M
1MRKStage 2 · wk 1692−0.6%
2BIIBStage 2 · wk 2192+11.6%
3LLYStage 2 · wk 190+13.5%
4AMGNStage 2 · wk 1687+10.1%
5OGNStage 2 · wk 2387+0.1%
6BMYStage 3 · wk 185+4.1%
7JNJStage 2 · wk 1683−0.6%
8PFEStage 2 · wk 877+7.9%
vs 52W High
0.0%
$283.30 lo$447.28 hi
Near 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 16
1w13w26w
Week 16, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
21.5%
200 DMA: $368.02 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
1.12x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
Short-term trend rising strongly
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+10.1%
3M
+19.6%
6M
+30.0%
YTD
+39.3%
1Y
+52.6%
Scan Membership
Breakout Watch
Latest: 2025-04-04
11 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 16 · Vol 1.12x
2026-10-21S2
Wk 16 · Vol 0.52x
2026-10-20S2
Wk 16 · Vol 0.80x
2026-10-19S2
Wk 15 · Vol 0.97x
2026-10-16S2
Wk 15 · Vol 0.93x
2026-10-15S2
Wk 15 · Vol 1.66x
2026-10-14S2
Wk 15 · Vol 1.10x
2026-10-13S2
Wk 15 · Vol 0.82x
2026-10-12S2
Wk 14 · Vol 0.61x
2026-10-09S2
Wk 14 · Vol 0.90x
2026-10-08S2
Wk 14 · Vol 0.84x
2026-10-07S2
Wk 14 · Vol 0.78x
Moving averages & range
50 DMA
$416.53
200 DMA
$368.02
52W High
$447.28
52W Low
$283.30
5D Low
$424.94
Resistance levels (recent highs)
20d High
$447.28
60d High
$447.28
120d High
$447.28
250d High
$447.28
Next resistance
Above all
P/E (TTM)
27.9
Forward 18.4
Earnings Growth (YoY)
+64.9%
Revenue +9.5%
ROE
+91.5%
Profit margin +23.0%
Dividend Yield
2.30%
P/B 20.8

Amgen: quick answers

What stage is Amgen in?

As of Oct 22, 2026, Amgen (AMGN) is in Stage 2, the uptrend phase. It entered Stage 2 on Jul 6, 2026 and is in week 16. What the four stages mean

Is Amgen in an uptrend?

Yes. Amgen is in a Stage 2 uptrend. It trades 21.5% above its 200-day average, which is rising.

How far is Amgen from its 52-week high?

Amgen closed at $447.28 on Oct 22, 2026, at its 52-week high. Its 52-week low is $283.30.

How has Amgen performed over the past year?

As of Oct 22, 2026, Amgen is up 52.6% over the past year and up 39.3% so far in 2026.

Which sector and industry is Amgen in?

Amgen is in the Drug Manufacturers - General industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - General

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.